Literature DB >> 32016053

Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes.

Antonino Passaniti1,2,3,4, Arif Hussain1,2,3,4.   

Abstract

Entities:  

Year:  2019        PMID: 32016053      PMCID: PMC6976458          DOI: 10.21037/atm.2019.09.109

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  17 in total

1.  Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.

Authors:  Gianluca Civenni; Roberto Bosotti; Andrea Timpanaro; Ramiro Vàzquez; Jessica Merulla; Shusil Pandit; Simona Rossi; Domenico Albino; Sara Allegrini; Abhishek Mitra; Sarah N Mapelli; Luca Vierling; Martina Giurdanella; Martina Marchetti; Alyssa Paganoni; Andrea Rinaldi; Marco Losa; Enrica Mira-Catò; Rocco D'Antuono; Diego Morone; Keyvan Rezai; Gioacchino D'Ambrosio; L'Houcine Ouafik; Sarah Mackenzie; Maria E Riveiro; Esteban Cvitkovic; Giuseppina M Carbone; Carlo V Catapano
Journal:  Cell Metab       Date:  2019-05-23       Impact factor: 27.287

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 3.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

4.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Authors:  Ian D Davis; Andrew J Martin; Martin R Stockler; Stephen Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy Parulekar; David W Pook; M Neil Reaume; Shahneen K Sandhu; Alvin Tan; T Hsiang Tan; Alastair Thomson; Emily Tu; Francisco Vera-Badillo; Scott G Williams; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

5.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury
Journal:  N Engl J Med       Date:  2019-05-31       Impact factor: 91.245

6.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

7.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

8.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 9.  Prostate cancer stem cells: a new target for therapy.

Authors:  Norman J Maitland; Anne T Collins
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

10.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

View more
  2 in total

1.  L22 ribosomal protein is involved in dynamin-related protein 1-mediated gastric carcinoma progression.

Authors:  Jianghong Cheng; Zizhuo Sha; Ruisan Zhang; Jinghao Ge; Peng Chen; Xuefeng Kuang; Jiazhi Chang; Kai Ren; Xianyang Luo; Shuai Chen; Xingchun Gou
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

2.  Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.

Authors:  Dehua Zhang; Muchun Zhang; Qifu Zhang; Zhiyi Zhao; Yong Nie
Journal:  Med Sci Monit       Date:  2020-07-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.